Accolade, Inc.
accolade.comNo Longer Reporting
The company has not filed an annual or quarterly report since its Q3 FY2025 10-Q, filed Jan 10, 2025. Its latest SEC filing is a SCHEDULE 13G/A from Aug 13, 2025.
10-Q for Q3 FY2025, filed Jan 10, 2025
The sections below describe the company as of the FY2024 annual report.
What Did They Do?
Provided personalized healthcare navigation, expert medical opinions, and virtual care to employers, health plans, and consumers.
10-K for FY2024, filed Apr 26, 2024
How Did They Make Money?
Employers and other commercial customers paid recurring per-member fees for access to advocacy and care; expert opinions were also priced per case, while virtual care was paid per visit or through consumer subscriptions.
10-K for FY2024, filed Apr 26, 2024We provide our solutions primarily to employers that deploy Accolade offerings to our members and to consumers who directly purchase our…View ↗
The Company generates revenue primarily from contracts with customers to access the Company’s advocacy, expert medical opinion, and virtual…View ↗
For the majority of expert medical opinion services, the Company satisfies these performance obligations over time and recognizes revenue…View ↗
-
10-K for FY2024, filed Apr 26, 2024
FY2024 revenue by product or service ↗
$414.3M
-
10-K for FY2024, filed Apr 26, 2024
$414.3M ↗
| Segment | Share | Revenue | How money arrives |
|---|---|---|---|
|
Access fees
Recurring
10-K for FY2024, filed Apr 26, 2024 |
73% |
Access fees, FY2024
$300.5M Sources
|
Recurring |
|
Usage-based fees
Usage-based
10-K for FY2024, filed Apr 26, 2024 |
27% |
Usage-based fees, FY2024
$113.8M Sources
|
Usage-based |
Who Were Their Customers?
Accolade sold principally through its direct sales team, with health-plan and government distribution agreements and brokers and consultants also helping reach employers. Employers bought solutions for employees and families; health plans, government entities, and consumers also bought services, with consumers purchasing virtual care directly.
10-K for FY2024, filed Apr 26, 2024Accolade enables our members to receive the right healthcare for their individual needs. We call it Personalized Healthcare. Accolade…View ↗
Sales Organization. We principally sell our solutions through our direct salesforce and distribution agreements with healthcare industry…View ↗
In addition to our direct sales organization, we maintain relationships with a range of third parties including brokers, benefits…View ↗
Did Revenues Turn Into Profits?
No. It lost $99.8M in FY2024.
10-K for FY2024, filed Apr 26, 2024
How Were They Changing?
- Net income
-
Sources
10-Q for Q3 FY2025, filed Jan 10, 2025
−$121.3MView ↗
- ▲ +476% (Loss)
- vs −$21.1M in Q3 FY2024
10-Q for Q3 FY2025, filed Jan 10, 2025
Open tableView ↗
-
Apr 8, 2025
Accolade completed a merger, converting shares into rights to cash payments.
Each share of common stock was converted into a right to receive $7.03 in cash.
Sources
8-K, filed Apr 8, 2025
Pursuant to the Merger Agreement, at the Effective Time, each share of common stock of the Company, par value $0.0001 per share (the…View ↗
Grew. Revenue grew 3.1x in 4 years, from $132.5M in FY2020 to $414.3M in FY2024, about 33% a year.
Broader care offerings
The earlier report centered on healthcare and benefits navigation and described PlushCare as a planned acquisition; the later report included integrated primary care and mental health support alongside navigation and expert medical opinions.
10-K for FY2021, filed May 7, 2021 10-K for FY2024, filed Apr 26, 2024
Who Did They Compete With?
Competes with Quantum Health and Included Health
10-K for FY2024, filed Apr 26, 2024We believe no single competitor offers a similarly comprehensive platform combining personalized, technology-enabled solutions with highly…View ↗
Loading...
